NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

Stock analysts at StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report issued on Monday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets cut their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 2.3 %

NYSE:NBY opened at $0.61 on Monday. The firm has a market capitalization of $2.98 million, a PE ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $11.45. The firm has a 50-day moving average price of $0.67 and a 200 day moving average price of $1.49.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.